Skip to content

Can Strength Training combined with Light Therapy reduce Insulin Resistance?

Strength Training and Photobiomodulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7rtcpp6
Enrollment
Unknown
Registered
2021-10-01
Start date
2022-03-28
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Interventions

After signing the informed consent form and answering questionnaires for medical clearance and to determine the level of physical activity, 48 (forty eight) overweight/obese (BMI > 25 kg/m2) participa
2) 1/3 (overweight/obese group that will perform strength training with reduced volume and will undergo placebo treatment)
3) 3/3-PBM (overweight/obese group that will perform strength training with normal volume and will undergo treatment with PBMt)
4) 1/3-PBM (overweight/obese group that will perform strength training with reduced volume and will undergo treatment with PBMt). After the end of the strength training period, oral glucose tolerance
C18.452.394.968.500

Sponsors

Universidade Federal dos Vales do Jequitinhonha e Mucuri
Lead Sponsor
Universidade Federal dos Vales do Jequitinhonha e Mucuri
Collaborator

Eligibility

Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Be male or female; Sign the informed consent form after reading and understanding it; BMI > 25 kg/m2; Be between 18 and 60 years old; Have stable body mass (variation less than 3 kg) in the last 3 months; Not being diagnosed, and not showing signs and symptoms of cardiovascular, metabolic or kidney disease from medical history; Being insufficiently active (>150 min/week of moderate to intense physical activity) based on a questionnaire; Being able to perform moderate to intense physical activity based on a questionnaire.

Exclusion criteria

Exclusion criteria: Being diabetic, or diagnosed with another metabolic disease; Being diagnosed with cardiovascular or kidney disease; Perform 150 min or more of moderate-intense physical activity per week; Not being able to perform physical exercise of moderate to intense intensity; Present signs or symptoms of metabolic, cardiovascular or renal disease; Make use of drugs with an effect on the metabolism, anti-inflammatory or anabolic steroids; Present musculoskeletal injury that prevents the performance of tests and strength training; Be pregnant; Have fasting blood glucose >125 mg/dl; Present blood glucose >199 mg/dl at 120 min of the oral glucose tolerance test; Missing 10% or more of training sessions.

Design outcomes

Primary

MeasureTime frame
Statistically significant change in the mean difference between and within groups after treatments in the result of the Cederholm insulin sensitivity index, calculated from the glucose and insulin results during the glucose tolerance test.

Secondary

MeasureTime frame
Statistically significant change in the mean difference between and within groups after treatments in 1) muscle strength (measured by the 1 RM test), 2) in fat mass, 3) in fat-free mass and 4) in visceral fat mass (measures through Dual Energy Radiological Absorptionmetry).

Countries

Brazil

Contacts

Public ContactFlávio de Castro Magalhães
flavio.magalhaes@ufvjm.edu.br+55 38 998663674

Outcome results

None listed

Source: REBEC (via WHO ICTRP)